Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934418 | 0.76 | MAP4K4 (0.33) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL29278540 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL11660148 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL26673743 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL13569111 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL23535657 | 0.74 | NPC1 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL2849283 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL1269053 | 0.74 | MAP4K4 (0.50) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL434570 | 0.74 | MAP4K4 (0.54) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL7829960 | 0.74 | HDAC2 (0.45) | MAP4K4ABL1MAPK8CSNK1A1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| US-11690850-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2021108198-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210154204-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-27 | — | — | US | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| EP-2758051-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043962-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690850-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | MAP4K4 402/4885ABL1 2547/4885MAPK8 459/4885 |
| US-20210154204-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | MAP4K4 402/4885ABL1 2547/4885MAPK8 459/4885 |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | MAP4K4 100/4885ABL1 27/4885MAPK8 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.